Aripiprazole Tablets USP, 30 mg recall — Ajanta Pharma Usa Inc (Class II)
Ajanta Pharma Usa Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Aripiprazole Tablets USP, 30 mg — a Class II recall, initiated 2026-05-27 and posted to the FDA enforcement report on 2026-06-24, under recall number D-0594-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.”. From the product description, the form is tablets, the strength given is 30 mg, the package is described as 30 tablets and it is marked Rx only. 1 National Drug Code number is printed in the record: 27241-056-03. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99046. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0594-2026 |
|---|---|
| FDA event ID | 99046 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Ajanta Pharma Usa Inc |
| Recall initiated | 2026-05-27 |
| Reported by FDA | 2026-06-24 |
| Report lag | 28 days from initiation to report |
| Distribution | U.S. Nationwide — Nationwide (US) |
| Firm location on record | NJ, United States |
| Product description (source) | Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-056-03. |
Reason reported by FDA
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
19 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 23-word product description above; each is a literal substring of it.
| Product named | Aripiprazole Tablets USP |
|---|---|
| Form | Tablets |
| Strength | 30 mg |
| Package | 30 tablets |
| NDC | 27241-056-03 |
| Marketing category | Rx only |
| Stated origin | India |
Other indexed recalls from Ajanta Pharma Usa Inc
2 indexed records name Ajanta Pharma Usa Inc as the recalling firm, across 2 FDA events, reported 2026-06-24 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Fenofibrate Capsules, 200 mg | D-0611-2026 | Class II | 200 mg · Capsules | 2026-07-01 |
Reported in the same month (2026-06)
74 enforcement reports carry a report date in 2026-06; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Alyacen 7/7/7, 0.5mg/0.035mg | D-0588-2026 | Glenmark Pharmaceuticals Inc., Usa | Class II | 2026-06-24 |
| VistaPharm, 25 Grams | D-0589-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 50 Grams | D-0590-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 25 Grams | D-0591-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 50 Grams | D-0592-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride | D-0593-2026 | Integradose Compounding Services LLC | Class II | 2026-06-24 |
| Buprenorphine HCl, 0.3 mg/mL | D-0596-2026 | Par Health Usa, LLC | Class II | 2026-06-24 |
| Pearson Quality Topical Anesthetic Gel (20% Benzocaine) | D-0600-2026 | Keystone Industries | Class II | 2026-06-24 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-06-24 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Quala Dental Products, 20 % | D-0601-2026 | Keystone Industries | 20 % · Gel | 2026-06-24 |
| DHP Topical Anesthetic Gel, 20% | D-0602-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| Burkhart topical anesthetic gel, 20 % | D-0603-2026 | Keystone Industries | 20 % · Gel | 2026-06-24 |
| Dental City TOPICAL ANESTHETIC GEL, 20% | D-0604-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| PureLife, 20% | D-0605-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| safco SensiCaine-Ultra (20% Benzocaine) | D-0606-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| Chlorthalidone Tablets, 25 mg | D-0610-2026 | Inventia Healthcare Ltd | 25 mg · Tablets | 2026-06-24 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 27241-056-03 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Ajanta Pharma Usa Inc (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0594-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0594-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-06-24
- Ingested
- 2026-08-22
- Record hash
ffde6ed3d6364aa8
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.